Share on StockTwits

Investment analysts at FBR Capital Markets assumed coverage on shares of Acceleron Pharma (NASDAQ:XLRN) in a note issued to investors on Wednesday. The firm set an “outperform” rating on the stock.

Acceleron Pharma (NASDAQ:XLRN) traded up 3.31% on Wednesday, hitting $29.37. 198,589 shares of the company’s stock traded hands. Acceleron Pharma has a 1-year low of $16.78 and a 1-year high of $57.89. The stock’s 50-day moving average is $30.02 and its 200-day moving average is $36.18. The company’s market cap is $923.8 million.

Acceleron Pharma (NASDAQ:XLRN) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.01. Analysts expect that Acceleron Pharma will post $-1.30 EPS for the current fiscal year.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.